Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

Temozolomide 38Radiotherapy 17Filgrastim 14Surgical Procedures, Operative 11Irinotecan 11Carmustine 10Carboplatin 10Radiation 9O(6)-benzylguanine 9Magnetic Resonance Spectroscopy 9Specimen Handling 7Granulocyte Colony-Stimulating Factor 7Flucytosine 7sargramostim 6Radiotherapy, Intensity-Modulated 5Peripheral Blood Stem Cell Transplantation 5Etoposide 5Erlotinib Hydrochloride 5Bevacizumab 5vocimagene amiretrorepvec 4Vorinostat 4Thiotepa 4Melphalan 4Lenalidomide 4IL13-PE38 4Genetic Therapy 4Cyclophosphamide 4Chemotherapy, Adjuvant 4Busulfan 4lonafarnib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Astrocytoma × regadenoson × Clear all
NCT03971734 2023-10-06

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Terminated
7 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡